Cervomed Inc (CRVO) Stock Price, Quote & News

Company Profile

CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurologic...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 744 4400

Website: www.cervomed.com

Address:

20 Park Plaza, Suite 424, Boston, United States

BPler Nov. 7 at 8:30 AM

As a marker to see, how $CRVO $EVH $FNKO will close 2025 with the companies punished in the past by the market but business-wise made improvements through 2025. At least one of them could double their value imho, but let's see.

0 · Reply

Doom_Gloom_AR Nov. 6 at 8:15 PM

$CRVO our day will come --- if they can raise the money without killing shareholders.

0 · Reply

BPler Nov. 5 at 7:11 PM

$CRVO Nearly 60 M in cash and grants, still aiming to collect the warrants; Updated November company deck https://ir.cervomed.com/static-files/3062c19c-fe1c-4e40-b04b-cef55f5f4121

2 · Reply

notreload_ai Nov. 5 at 3:01 PM

$RYTM , $VNDA , $VRCA , $CRVO , $VTYX ... Oppenheimer downgrades Rhythm Pharmaceuticals after major gains, while analysts issue fresh Buy ratings on Vanda, Verrica, CervoMed, and Ventyx highlighting key catalysts and growth potential. https://notreload.xyz/biotech-analyst-moves-rytm-cut-vnda-vrca-crvo-vtyx-upgraded/

0 · Reply

BPler Nov. 5 at 2:36 PM

$CRVO 8% up with only 7k volume ... this ticker needs just one whale to correct the price back up.

0 · Reply

JarvisFlow Nov. 5 at 11:35 AM

HC Wainwright & Co. has updated their rating for CervoMed ( $CRVO ) to Buy with a price target of 25.

0 · Reply

BPler Nov. 4 at 7:32 PM

I know the market, crypto and even mighty pokemon is tanking but this ticker moves unreal $CRVO If there is not a massive movement AH I am out of thoughts.

1 · Reply

BPler Nov. 4 at 4:43 PM

$CRVO https://www.marketscreener.com/news/cervomed-announces-alignment-with-fda-on-registration-path-for-neflamapimod-in-dementia-with-lewy-bo-ce7d5cded08cfe24

1 · Reply

Messerschmittbf109 Nov. 4 at 4:42 PM

$CRVO boring. Watching their dirty games

0 · Reply

LilyBurger Nov. 4 at 3:50 PM

$CRVO 🥱 Boring Not selling until 25+

0 · Reply

CervoMed to Present at the Emerging Growth Conference

Oct 8, 2025, 11:54 AM EDT - 4 weeks ago

CervoMed Drug Cut Dementia Progression Risk By 75% In Trial

Oct 8, 2025, 7:00 AM EDT - 4 weeks ago

CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies

Oct 2, 2025, 8:00 AM EDT - 5 weeks ago

CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

Sep 17, 2025, 7:30 AM EDT - 7 weeks ago

CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference

Sep 3, 2025, 8:00 AM EDT - 2 months ago

CervoMed to Participate in Upcoming Investor Conferences

Jul 28, 2025, 11:20 AM EDT - 3 months ago

CervoMed's Dementia Data Show Slowed Disease Progression

Jul 28, 2025, 7:00 AM EDT - 3 months ago

CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration

Jul 8, 2025, 7:00 AM EDT - 4 months ago

CervoMed Announces Late-Breaking Presentations at Alzheimer's Association® International Congress 2025

May 12, 2025, 8:00 AM EDT - 6 months ago

CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Mar 31, 2025, 2:34 PM EDT - 7 months ago

Biotech Stocks Q1 2025 Recap: Winners And Underperformers

CMRX CVS GERN LLY NVO SEPN

Mar 25, 2025, 8:00 AM EDT - 8 months ago

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)

Mar 22, 2025, 2:55 AM EDT - 8 months ago

CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats

Mar 10, 2025, 4:05 PM EDT - 8 months ago

CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

Jan 29, 2025, 8:00 AM EST - 10 months ago

CervoMed to Present at the 8th International Lewy Body Dementia Conference

Dec 12, 2024, 7:00 AM EST - 11 months ago

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 10, 2024, 11:37 AM EST - 11 months ago

CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets

Dec 10, 2024, 10:10 AM EST - 11 months ago

CervoMed's stock craters 77% after failed trial of treatment for rare brain disease

Dec 10, 2024, 7:33 AM EST - 11 months ago

CervoMed's dementia drug fails to meet mid-stage trial goals

Dec 10, 2024, 7:00 AM EST - 11 months ago

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

Nov 27, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

Nov 12, 2024, 7:00 AM EST - 1 year ago

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Nov 8, 2024, 9:55 AM EST - 1 year ago

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

Nov 4, 2024, 8:00 AM EST - 1 year ago

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

Oct 29, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

Oct 2, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

Aug 22, 2024, 8:00 AM EDT - 1 year ago

CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies

Jul 30, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference

Jul 17, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in the Emerging Growth Conference

Jul 11, 2024, 8:51 AM EDT - 1 year ago

CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

Jun 11, 2024, 8:00 AM EDT - 1 year ago

CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies

May 20, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Appoint William Elder as Chief Financial Officer

May 15, 2024, 8:00 AM EDT - 1 year ago

CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Apr 2, 2024, 2:59 AM EDT - 1 year ago

CervoMed: H2 2024 Data For DLB Program A Major Inflection Point

Apr 1, 2024, 8:00 AM EDT - 1 year ago

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Mar 28, 2024, 8:30 AM EDT - 1 year ago

CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

Mar 5, 2024, 8:00 AM EST - 1 year ago

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

Feb 21, 2024, 8:00 AM EST - 1 year ago

CervoMed to Participate in the BIO CEO and Investor Conference

Feb 12, 2024, 8:00 AM EST - 1 year ago

CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies

Feb 7, 2024, 8:30 AM EST - 1 year ago

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

Feb 5, 2024, 8:00 AM EST - 1 year ago

CervoMed to Participate in the Emerging Growth Conference 67

Jan 5, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the Emerging Growth Conference 66

Nov 13, 2023, 7:00 AM EST - 2 years ago

CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights

Oct 25, 2023, 2:50 PM EDT - 2 years ago

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy Bodies

Oct 24, 2023, 7:00 AM EDT - 2 years ago

CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major Dementias

Oct 18, 2023, 7:00 AM EDT - 2 years ago

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Phase 2b Neflamapimod Program for the Treatment of Patients with Dementia with Lewy Bodies

Oct 5, 2023, 7:00 AM EDT - 2 years ago

CervoMed to Present at the 2023 Roth Healthcare Opportunities Conference

Sep 5, 2023, 7:00 AM EDT - 2 years ago

CervoMed to Present at H.C. Wainwright 25th Annual Global Investment Conference

Aug 16, 2023, 1:58 PM EDT - 2 years ago

CervoMed Announces Completion of Merger with EIP Pharma

Aug 15, 2023, 4:01 PM EDT - 2 years ago

Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma

BPler Nov. 7 at 8:30 AM

0 · Reply

Doom_Gloom_AR Nov. 6 at 8:15 PM

$CRVO our day will come --- if they can raise the money without killing shareholders.

0 · Reply

BPler Nov. 5 at 7:11 PM

$CRVO Nearly 60 M in cash and grants, still aiming to collect the warrants; Updated November company deck https://ir.cervomed.com/static-files/3062c19c-fe1c-4e40-b04b-cef55f5f4121

2 · Reply

notreload_ai Nov. 5 at 3:01 PM

0 · Reply

BPler Nov. 5 at 2:36 PM

$CRVO 8% up with only 7k volume ... this ticker needs just one whale to correct the price back up.

0 · Reply

JarvisFlow Nov. 5 at 11:35 AM

HC Wainwright & Co. has updated their rating for CervoMed ( $CRVO ) to Buy with a price target of 25.

0 · Reply

BPler Nov. 4 at 7:32 PM

I know the market, crypto and even mighty pokemon is tanking but this ticker moves unreal $CRVO If there is not a massive movement AH I am out of thoughts.

1 · Reply

BPler Nov. 4 at 4:43 PM

$CRVO https://www.marketscreener.com/news/cervomed-announces-alignment-with-fda-on-registration-path-for-neflamapimod-in-dementia-with-lewy-bo-ce7d5cded08cfe24

1 · Reply

Messerschmittbf109 Nov. 4 at 4:42 PM

$CRVO boring. Watching their dirty games

0 · Reply

LilyBurger Nov. 4 at 3:50 PM

$CRVO 🥱 Boring Not selling until 25+

0 · Reply

1K21Mil Nov. 4 at 3:20 PM

$CRVO This usually has delayed response. So, going over $9 by Friday won’t be surprising. It seems a good swing trade, buy below $7 and sell close to $10. Rinse and repeat.

1 · Reply

Disinformation_Consumer Nov. 4 at 3:14 PM

$CRVO calling it now. Close under $7.

1 · Reply

Stu_padasso Nov. 4 at 2:29 PM

$CRVO going red? cool dilution coming i guess

1 · Reply

JarvisFlow Nov. 4 at 1:41 PM

D. Boral Capital has adjusted their stance on CervoMed ( $CRVO ), setting the rating to Buy with a target price of 31.

1 · Reply

BPler Nov. 4 at 12:55 PM

$CRVO Can we please gap back over 30 already?

1 · Reply

OpenOutcrier Nov. 4 at 12:38 PM

$CRVO (+10.7% pre) CervoMed Announces Alignment with FDA on Registration Path for Neflamapimod in Dementia with Lewy Bodies https://ooc.bz/l/82963

0 · Reply

Disinformation_Consumer Nov. 4 at 12:36 PM

$CRVO for any newcomers who saw this stock in the top gainers today, be very careful. This company is not profitable and will not be profitable for a long time. They may never be profitable. It is prone to rapid share price fluctations and after hours swings. The only way to win is to get in when it’s low.

0 · Reply

Disinformation_Consumer Nov. 4 at 12:22 PM

$CRVO ok we got phase 3 feedback. Glad i held on. Should probably think about doing some more profit taking before the dilution hits.

0 · Reply

Doom_Gloom_AR Nov. 4 at 3:52 AM

$CRVO No interest in this company but they now have reached stat sig in not one but two trials for LBD. That's crazy. Never been done before. I have a tiny position, I trade in and out a bunch. Part of my brain says I should but a very large position, however I'm going to wait to see if they bring in some funding without triple warrant coverage or something horrible. I would love to see some top tier biotech funds here. They have RA but I want ADAR1.

0 · Reply

JimmyGatz Nov. 4 at 1:38 AM

$CRVO Hope the shutdown ends soon... Can't get any approval without the FDA...

2 · Reply

Disinformation_Consumer Nov. 3 at 2:20 PM

$CRVO which one of you bastards bought 800 shares and sent it up 4%?

0 · Reply

Messerschmittbf109 Oct. 31 at 10:39 PM

Beautiful 🤩 $JASPER.X $CRVO

1 · Reply

Market Cap	67.92M
Revenue (ttm)	9.74M
Net Income (ttm)	-16.29M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-167.25%
Debt to Equity Ratio	0.00

Volume	34,900
Avg Vol	99,524
Day's Range	N/A - N/A
Shares Out	9.25M
Stochastic %K	55%
Beta	-0.89
Analysts	Strong Sell
Price Target	$20.57